M.D. Anderson Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count).
M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.
M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.
Top-decile sponsor footprint
M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,692 total, page 34 of 54
Minocycline Study in Pancreatic Cancer Patients
NCT01693523
Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System
NCT01596127
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
NCT01490723
Dexamethasone Dyspnea Study
NCT01670097
Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study
NCT01737671
Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
NCT01596140
Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL
NCT01752426
Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells
NCT01362452
Preventing Sexual Dysfunction With Aromatase Inhibitors
NCT01603303
Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT01718743
Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
NCT01585194
Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer
NCT01725165
Allogeneic Stem Cell Transplant for CLL
NCT01629511
Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
NCT01636609
Gene Expression in Hyperparathyroidism
NCT03044600
Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk
NCT01720225
Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas
NCT01730586
Using Multimedia Approaches to Communicate Probabilities in Patient Decision Aids for Low-Literacy Populations: Randomized Trial
NCT02151032
Magnetic Resonance Imaging of Gynecologic Malignancies Involving the Vagina
NCT01703195
TKI 258 in Von Hippel-Lindau Syndrome (VHL)
NCT01266070
Doxycycline, Temozolomide and Ipilimumab in Melanoma
NCT01590082
Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma
NCT01590732
CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
NCT01664910
Brief Guided Relaxation for Women Undergoing Stereotactic Breast Biopsy
NCT03023215
Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
NCT01701986
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
NCT01392183
Magnetic Resonance Imaging (MRI) Brachytherapy Applicator Study
NCT01706705
Adaptation of the American Cancer Society (ACS) Early Detection of Prostate Cancer Patient Decision Aid for Spanish Speaking Men
NCT01447186
REcovery of Left Ventricular Dysfunction in CAncer Patients (RECAP Trial)
NCT02543294
The Effect of Dexmedetomidine of the Immune System
NCT01692210
An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor
NCT01619774
Exemestane-RAD001-Metformin
NCT01627067
Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)
NCT01460498
R-21 Colorectal Cancer Screening (CRCS) Pilot Trial
NCT01492049
A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy
NCT01624220
Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2
NCT01593020
Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT)
NCT01511081
A Study of the HSP90 Inhibitor AUY922
NCT01485536
Lacosamide in Preventing Seizures in Participants With Malignant Glioma
NCT01432171
Prospective Study to Determine Impact of Early Palliative Care Consult on Quality of Life (QOL), Cancer Related Symptoms In Advanced Lung Cancer Patients: Thoracic Pilot Project
NCT02459002
Genomic Profiling Assay in Phase I
NCT02437617
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
NCT01471067
Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
NCT01505868
Study of Vemurafenib, Carboplatin, and Paclitaxel
NCT01636622
Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias
NCT01396499
A Mixed-Methods Approach to Understanding Factors Associated With Cervical Cancer Screening Utilization Among Low-Income, HIV-Positive Women
NCT01605656
Imaging Study Compare 4DCT Image
NCT01626001
Social Determinants and Smoking Cessation
NCT01310842
Minocycline Study in Non Small Cell Lung Cancer (NSCLC) Patients for Chemoradiation Therapy
NCT01636934
Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
NCT01582152
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 748 |
| Phase 2 | 971 |
| Phase 3 | 96 |
| Phase 4 | 28 |
Therapeutic Areas
What is open in the M.D. Anderson Cancer Center pipeline
549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).
Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).
Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.